JP2018516539A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516539A5 JP2018516539A5 JP2017553320A JP2017553320A JP2018516539A5 JP 2018516539 A5 JP2018516539 A5 JP 2018516539A5 JP 2017553320 A JP2017553320 A JP 2017553320A JP 2017553320 A JP2017553320 A JP 2017553320A JP 2018516539 A5 JP2018516539 A5 JP 2018516539A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- group
- sequence
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510185602.3 | 2015-04-17 | ||
| CN201510185602 | 2015-04-17 | ||
| CN201510300885.1A CN106188293A (zh) | 2015-04-17 | 2015-06-04 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| CN201510300885.1 | 2015-06-04 | ||
| PCT/CN2016/078699 WO2016165580A1 (zh) | 2015-04-17 | 2016-04-07 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516539A JP2018516539A (ja) | 2018-06-28 |
| JP2018516539A5 true JP2018516539A5 (https=) | 2019-04-25 |
Family
ID=57459461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553320A Pending JP2018516539A (ja) | 2015-04-17 | 2016-04-07 | 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10543284B2 (https=) |
| EP (1) | EP3284751A4 (https=) |
| JP (1) | JP2018516539A (https=) |
| KR (1) | KR20170138451A (https=) |
| CN (3) | CN106188293A (https=) |
| AU (1) | AU2016248357A1 (https=) |
| BR (1) | BR112017021245A2 (https=) |
| CA (1) | CA2982777A1 (https=) |
| MX (1) | MX2017012965A (https=) |
| RU (1) | RU2017135257A (https=) |
| TW (1) | TWI731856B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127790A1 (zh) * | 2015-02-15 | 2016-08-18 | 江苏恒瑞医药股份有限公司 | 配体-细胞毒性药物偶联物、其制备方法及其应用 |
| CA3015098A1 (en) * | 2016-02-26 | 2017-08-31 | Jiangsu Hengrui Medicine Co., Ltd. | New toxin and method for preparing intermediate thereof |
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| US20180230218A1 (en) * | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| MX2019011635A (es) | 2017-03-30 | 2020-01-20 | Jiangsu Hengrui Medicine Co | Método para la preparación de conjugados anticuerpo-fármaco. |
| CN110382008A (zh) * | 2017-06-06 | 2019-10-25 | 江苏恒瑞医药股份有限公司 | 一种含c-Met抗体药物偶联物的药物组合物及其用途 |
| US10947316B2 (en) * | 2017-06-15 | 2021-03-16 | Development Center For Biotechnology | Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof |
| WO2019034176A1 (zh) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CN110090306B (zh) * | 2018-01-31 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 双醛连接臂的配体-药物偶联物、其制备方法及其应用 |
| KR102221755B1 (ko) * | 2018-05-02 | 2021-03-02 | (주)에임드바이오 | c-Met에 특이적으로 결합하는 항체 및 그의 용도 |
| WO2019242505A1 (zh) | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| CA3114474A1 (en) * | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| KR102396194B1 (ko) * | 2018-12-07 | 2022-05-10 | 서울대학교 산학협력단 | 항 c-Met 아고니스트 항체 및 이의 용도 |
| US20230072897A1 (en) * | 2019-06-06 | 2023-03-09 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-b7-h4 antibody-drug conjugate and medicinal use thereof |
| AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
| EP3828196A4 (en) * | 2019-09-29 | 2022-04-27 | MabPlex International Co., Ltd. | METHOD FOR PREPARING AN INTERMEDIATE ANTIBODY-DRUG CONJUGATE BY ACID METHOD AND APPLICATION THEREOF |
| CN115103858B (zh) * | 2020-03-25 | 2025-07-15 | 江苏恒瑞医药股份有限公司 | 一种抗体药物偶联物的制备方法 |
| WO2021190564A1 (zh) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| TW202200212A (zh) * | 2020-05-03 | 2022-01-01 | 中國大陸商聯寧（蘇州）生物製藥有限公司 | 包含抗-trop-2抗體之抗體藥物結合物 |
| CN112521507B (zh) * | 2020-08-10 | 2021-06-08 | 北京鼎成肽源生物技术有限公司 | 抗人c-Met人鼠嵌合单克隆抗体及其应用 |
| US20220056111A1 (en) * | 2020-08-11 | 2022-02-24 | Yurogen Biosystems Llc | MONOCLONAL ANTIBODY AGAINST SPIKE S1 PROTEIN OF SARS-CoV-2 AND USE THEREOFOF |
| EP4129335A4 (en) * | 2020-09-01 | 2024-04-24 | RemeGen Co., Ltd. | ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS |
| WO2022078279A1 (zh) * | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| CN112683857B (zh) * | 2021-01-06 | 2022-10-14 | 上海药明生物医药有限公司 | 一种通过评估分析物的溶剂效应对亲和力实验的影响来指导spr检测前处理的方法 |
| CN112924665B (zh) * | 2021-02-19 | 2023-10-03 | 山东莱博生物科技有限公司 | 一种抗体辣根过氧化物酶标记物及其制备与应用 |
| WO2022205316A1 (en) * | 2021-04-01 | 2022-10-06 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates comprising effector molecules and uses thereof |
| IL305335A (en) * | 2021-02-25 | 2023-10-01 | Allygen Group | Targeted conjugates containing activator molecules and their uses |
| TW202547842A (zh) * | 2021-04-29 | 2025-12-16 | 愛爾蘭商艾伯維製造管理無限公司 | 抗c-Met抗體藥物結合物 |
| EP4372001A4 (en) * | 2021-07-14 | 2025-02-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF |
| CN115975030B (zh) * | 2021-09-30 | 2023-09-26 | 杭州邦顺制药有限公司 | 抗cd39抗体-药物偶联物及其用途 |
| CN118159567A (zh) * | 2021-11-05 | 2024-06-07 | 正大天晴药业集团股份有限公司 | 抗c-Met抗体及其应用 |
| CN115963233B (zh) * | 2022-03-17 | 2025-06-03 | 南京药明康德新药开发有限公司 | 一种评估抗体偶联药物稳定性的方法 |
| EP4624493A1 (en) * | 2022-11-24 | 2025-10-01 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr |
| WO2024131835A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
| WO2024131846A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| KR20250127137A (ko) * | 2022-12-23 | 2025-08-26 | 메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 | 항-cmet 항체, 항체-약물 접합체, 이의 제조 방법 및 용도 |
| CN120835792A (zh) * | 2023-05-24 | 2025-10-24 | 杭州禧鹤生物科技有限公司 | 抗体-药物偶联物靶向治疗前列腺癌和其他肿瘤 |
| CN121487754A (zh) * | 2023-07-25 | 2026-02-06 | 江苏恒瑞医药股份有限公司 | 靶向c-Met的抗体-药物偶联物及其医药用途 |
| WO2025060962A1 (en) * | 2023-09-21 | 2025-03-27 | Beijing Neox Biotech Limited | Multi-specific antibodies and uses thereof |
| WO2025108427A1 (zh) * | 2023-11-23 | 2025-05-30 | 橙帆生物医药公司 | 结合分子及抗体药物偶联物和用途 |
| WO2025146620A1 (ko) * | 2024-01-02 | 2025-07-10 | 주식회사 종근당 | 항 c-met 항체를 포함하는 항암 조합물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545613T3 (da) * | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| EP2478912B1 (en) * | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| CA2575402A1 (en) * | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| US7750116B1 (en) * | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| UY32914A (es) * | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Anticuerpos que se usan específicamente al receptor epha2 |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| CN105452297B (zh) * | 2013-04-30 | 2019-10-11 | 新加坡科技研究局 | mAb 2抗-Met抗体 |
-
2015
- 2015-06-04 CN CN201510300885.1A patent/CN106188293A/zh active Pending
-
2016
- 2016-04-07 BR BR112017021245-5A patent/BR112017021245A2/pt not_active Application Discontinuation
- 2016-04-07 EP EP16779555.8A patent/EP3284751A4/en not_active Withdrawn
- 2016-04-07 JP JP2017553320A patent/JP2018516539A/ja active Pending
- 2016-04-07 RU RU2017135257A patent/RU2017135257A/ru not_active Application Discontinuation
- 2016-04-07 CA CA2982777A patent/CA2982777A1/en not_active Abandoned
- 2016-04-07 US US15/565,928 patent/US10543284B2/en active Active
- 2016-04-07 CN CN201910217709.XA patent/CN111196853A/zh active Pending
- 2016-04-07 CN CN201680001857.2A patent/CN106687480B/zh active Active
- 2016-04-07 AU AU2016248357A patent/AU2016248357A1/en not_active Abandoned
- 2016-04-07 MX MX2017012965A patent/MX2017012965A/es unknown
- 2016-04-07 KR KR1020177031260A patent/KR20170138451A/ko not_active Withdrawn
- 2016-04-15 TW TW105111792A patent/TWI731856B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516539A5 (https=) | ||
| RU2017135257A (ru) | Антитело к с-мет и конъюгат антитело к с-мет-цитотоксическое лекарственное средство, и их фармацевтическое применение | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| TWI895608B (zh) | 抗c-Met抗體藥物結合物 | |
| JP2025516158A (ja) | 抗体－薬物複合体並びにその調製方法及び使用 | |
| JP2024545233A (ja) | カンプトテシン化合物及びそのコンジュゲート | |
| JP2026026483A (ja) | 標的化デンドリマー複合体 | |
| TW202421204A (zh) | 抗體—藥物結合物及其製備方法及用途 | |
| RU2019107392A (ru) | Медицинское применение конъюгата антитело против c-met цитотоксическое лекарственное средство | |
| TWI864640B (zh) | Gpc3抗體藥物偶聯物及其用途 | |
| CA3075896A1 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| CN118079013A (zh) | 稠环类化合物及其偶联物和用途 | |
| CN118302199A (zh) | 抗cdh6抗体及其抗体-药物偶联物 | |
| KR20250112249A (ko) | 융합된 고리 화합물, 이의 접합체 및 이의 용도 | |
| CN119053607B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| CN119300868B (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| WO2025045015A1 (zh) | 抗体-药物缀合物及其制备方法和用途 | |
| CN117534725A (zh) | 连接子、连接子-药物缀合物、配体-药物偶联物及其应用 | |
| AU2024286929A1 (en) | Anti-b7-h3 antibody or fragment thereof, and antibody drug conjugate targeting b7-h3 | |
| CN121712532A (zh) | 喜树碱类化合物及其偶联物、其制备方法和用途 | |
| TW202613169A (zh) | 一種抗dll3抗體、抗體藥物偶聯物及其應用 | |
| KR20250128359A (ko) | 항 b7h3 및 pd-l1의 이중특이성 항체-약물 접합체 및 이의 제조 방법과 용도 | |
| CA3286471A1 (en) | Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof | |
| EP4692118A1 (en) | Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof | |
| CN120923576A (zh) | 一种海兔毒素类似物及其配体偶联药物及其制备方法和应用 |